Showing results (21-30 of 104) with videos related to

Sort By:
Pageof 11
AIDS (London, England)|November 7, 2015
Obesity is associated with greater inflammation and monocyte activation among HIV-infected adults receiving antiretroviral therapyLois J Conley, Timothy J Bush, Adam W Rupert, et al.
AIDS (London, England)|September 29, 2012
Platelet count kinetics following interruption of antiretroviral treatmentEva Zetterberg, Jacqueline Neuhaus, Jason V Baker, et al.
AIDS Care|October 19, 2022
The relationship between substance use and physical activity among people living with HIV, chronic pain, and symptoms of depression: a cross-sectional analysisEmily M Cherenack, Michael D Stein, Ana M Abrantes, et al.
Surgical Infections|April 18, 2007
Inguinal lymph node biopsy in patients infected with the human immunodeficiency virus is safeDavid E Skarda, Jodie H Taylor, Jeffrey G Chipman, et al.
The Journal of Infectious Diseases|December 16, 2017
Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) StudyAndreas Ronit, Shweta Sharma, Jason V Baker, et al.
The American Journal of Cardiology|January 2, 2013
Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infectionMihir Gupta, Christopher J Miller, Jason V Baker, et al.
BMC Infectious Diseases|August 31, 2013
Human immunodeficiency virus, hepatitis C, and inflammatory biomarkers in individuals with alcohol problems: a cross-sectional studyKaku A Armah, Emily K Quinn, Debbie M Cheng, et al.
Frontiers in Immunology|June 3, 2021
The Role of Inflammation and Immune Activation on Circulating Endothelial Progenitor Cells in Chronic HIV InfectionZiang Zhu, Tong Li, Jinya Chen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 22, 2019
Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) TrialJeffrey A Boatman, Jason V Baker, Sean Emery, et al.
Plos One|October 20, 2012
Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trialJason V Baker, Kathleen Huppler Hullsiek, Rachel Prosser, et al.
Pageof 11